title: Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
authors.affiliation: Division de Investigación Clínica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
authors.forename: Myrna
authors.initials: M
authors.lastname: Candelaria
authors.forename: Aquileo
authors.initials: A
authors.lastname: Herrera
authors.forename: Juan
authors.initials: J
authors.lastname: Labardini
authors.forename: Aurora
authors.initials: A
authors.lastname: González-Fierro
authors.forename: Catalina
authors.initials: C
authors.lastname: Trejo-Becerril
authors.forename: Lucía
authors.initials: L
authors.lastname: Taja-Chayeb
authors.forename: Enrique
authors.initials: E
authors.lastname: Pérez-Cárdenas
authors.forename: Erick
authors.initials: E
authors.lastname: de la Cruz-Hernández
authors.forename: Daymi
authors.initials: D
authors.lastname: Arias-Bofill
authors.forename: Silvia
authors.initials: S
authors.lastname: Vidal
authors.forename: Eduardo
authors.initials: E
authors.lastname: Cervera
authors.forename: Alfonso
authors.initials: A
authors.lastname: Dueñas-Gonzalez